1. Signaling Pathways
  2. Immunology/Inflammation
  3. Transmembrane Glycoprotein

Transmembrane Glycoprotein

Transmembrane Glycoprotein

Transmembrane glycoproteins are important components of cell membranes and are characterized by oligosaccharide chains covalently linked to polypeptide chains. Glycosylation sites are mainly located in their extracellular regions, achieved by N-linked glycosylation (linked to asparagine residues) or O-linked glycosylation (linked to serine or threonine residues). Sugar chains not only provide structural stability to proteins but also confer functional specificity. Many transmembrane glycoproteins are receptors, such as G protein-coupled receptors (GPCRs) and receptor tyrosine kinases (RTKs). Most (clusters of differentiation)CD molecules are also transmembrane glycoproteins expressed on the surface of antigen-presenting cells[1][2].

Transmembrane Glycoprotein Related Products (367):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P991624
    Anti-UNC5B Antibody (YW88)
    Inhibitor
    Anti-UNC5B Antibody (YW88) is a monoclonal antibody against UNC5B. Anti-UNC5B Antibody (YW88) can inhibit the binding of Netrin-1 to Unc5B. Anti-UNC5B Antibody (YW88) can be used in research on angiogenesis.
    Anti-UNC5B Antibody (YW88)
  • HY-P990126
    Anti-Rat CD8α Antibody (OX-8)
    Inhibitor
    Anti-Rat CD8α Antibody (OX-8) is an anti-rat CD8α IgG1 monoclonal antibody. Anti-Rat CD8α Antibody (OX-8) can deplete CD8+ T cells. Anti-Rat CD8α Antibody (OX-8) can enhance airway remodeling. Anti-Rat CD8α Antibody (OX-8) can be used for researches on allergic conditions and infections such as RHV-rn1 virus infection and asthma.
    Anti-Rat CD8α Antibody (OX-8)
  • HY-P991723
    Varsetatug
    Inhibitor
    Varsetatug (CX-2051 antibody) is a humanized IgG1κ monoclonal antibody inhibitor targeting EpCAM/TROP1/CD326. Varsetatug serves as the antibody component of the ADC compound CX-2051. It can be used in research on cancers including breast cancer, prostate cancer and ovarian cancer.
    Varsetatug
  • HY-171792
    BMS-986497
    Inhibitor
    BMS-986497 (ORM-6151) is a CD33-targeting antibody-conjugated GSPT1 degrader. BMS-986497 delivers the GSPT1 degrader SMol006 to CD33-expressing cells and induces GSPT1 protein degradation. BMS-986497 shows potential for research on acute myeloid leukemia (AML).
    BMS-986497
  • HY-P99381
    XmAb 5592
    Inhibitor 99.51%
    XmAb 5592 is a humanized, Fc-engineered anti-HM1.24 antibody with enhanced binding to FcγRIIIa and FcγRIIa receptors, augments HM1.24-specific multiple myeloma (MM) cells lysis in vitro via antibody-dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP).
    XmAb 5592
  • HY-113481
    Prostaglandin E3
    Inhibitor ≥99.0%
    Prostaglandin E3 is an eicosanoid derived from eicosapentaenoic acid. Prostaglandin E3 inhibits polarization towards M1 but promotes polarization of M2a macrophages. Prostaglandin E3 shows anti-inflammatory and anti-tumor activity.
    Prostaglandin E3
  • HY-170589
    GPR17 antagonist 1
    Antagonist 98.95%
    GPR17 antagonist 1 (compound 978) is a GPR17 antagonist. GPR17 antagonist 1 can be used in the study of diabetes and obesity.
    GPR17 antagonist 1
  • HY-P990157
    Anti-Mouse Thy1/CD90 Antibody (M5/49.4.1)
    Inhibitor
    Anti-Mouse Thy1/CD90 Antibody (M5/49.4.1) is an anti-mouse Thy1/CD90 IgG2a monoclonal antibody. Anti-Mouse Thy1/CD90 Antibody (M5/49.4.1) can clear T cells from the spleen and bone marrow. Anti-Mouse Thy1/CD90 Antibody (M5/49.4.1) can be used for researches on immunology and inflammation conditions such as colitis.
    Anti-Mouse Thy1/CD90 Antibody (M5/49.4.1)
  • HY-P2284
    AD 01
    Ligand 99.98%
    AD 01, a 24 amino acid peptide of FKBPL (FK506-binding protein like), possesses potent anti-angiogenic activity. AD 01 bind to the CD44 receptor and inhibit tumour cell migration in a CD44 dependant manner.
    AD 01
  • HY-P10551
    ApoA-I mimetic peptide 5A
    Inhibitor
    ApoA-I mimetic peptide 5A is a synthetic peptide molecule designed based on the structure and function of naturally occurring apolipoprotein A-I (Apo A-I). ApoA-I mimetic peptide 5A can promote the efflux of cholesterol from cells and help reduce the accumulation of cholesterol in cells. ApoA-I mimetic peptide 5A also shows anti-inflammatory activity and can reduce inflammatory markers in blood and tissues. ApoA-I mimetic peptide 5A can be used in the study of cardiovascular diseases.
    ApoA-I mimetic peptide 5A
  • HY-P991181
    VTX-1218
    Inhibitor 99.9%
    VTX-1218 is a VSIG4 inhibitor with human Kd 7.4 nM. VTX-1218 blocks VSIG4 activity, relieves VSIG4-mediated macrophage suppression, repolarizes tumor-associated macrophages and induces T cell activation. VTX-1218 upregulates cytokines and chemokines linked to immune cell recruitment. VTX-1218 can be used for the research of multiple cancer types.
    VTX-1218
  • HY-P990704
    Rilvegostomig
    Inhibitor 99.00%
    Rilvegostomig (AZD-2936) is a bispecific humanized IgG1 antibody targeting PD-1 and TIGIT. Rilvegostomig induces tumor growth inhibition and modulates the tumor immune microenvironment. Rilvegostomig exhibits anti-tumor activity in metastatic non-small cell lung cancer (without prior immune checkpoint inhibitor treatment). Rilvegostomig can be used in research related to metastatic non-small cell lung cancer and endometrial cancer.
    Rilvegostomig
  • HY-P990259
    Anti-Mouse CD96 Antibody (3.3)
    Inhibitor
    Anti-Mouse CD96 Antibody (3.3) is a rat-derived anti-mouse CD96 IgG1 λ type antibody inhibitor. Anti-Mouse CD96 Antibody (3.3) blocks binding of CD155 to CD96. Anti-Mouse CD96 Antibody (3.3) can enhance the antitumor efficacy of multiple immune-checkpoint inhibitors. Anti-Mouse CD96 Antibody (3.3) shows potent anti-tumor and anti-metastatic activity in various tumor models. Anti-Mouse CD96 Antibody (3.3) can be used for the researches of cancer and inflammation, such as mammary carcinoma.
    Anti-Mouse CD96 Antibody (3.3)
  • HY-P990360
    Anti-CD9 Antibody
    99.52%
    The Anti-CD9 Antibody is a humanized antibody expressed in CHO, targeting CD9. The Anti-CD9 Antibody is equipped with huIgG1 heavy chains and huκ light chains, with a predicted molecular weight (MW) of 145.98 kDa. The isotype control for Anti-CD9 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-CD9 Antibody
  • HY-P990902
    Atigotatug
    Ligand ≥99.0%
    Atigotatug (BMS-986012) is a fully human IgG1 antibody binds specifically to FucGM1 with an EC50 of 0.15 nmol/L for FucGM1. Atigotatug is a FcγRIIIa ligand with a Kd of 21 nmol/L. Atigotatug demonstrates antitumor efficacy in multiple mouse small cell lung cancer models.
    Atigotatug
  • HY-P991187
    Anti-TM4SF1 Antibody (AGX-A07)
    Inhibitor 99.01%
    Anti-TM4SF1 Antibody (AGX-A07) is a humanized IgG1 monoclonal antibody that targets TM4SF1. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-TM4SF1 Antibody (AGX-A07)
  • HY-P992030
    FB102
    FB102 is an anti-human CD122 (IL-2Rβ) monoclonal antibody with selective activity. FB102 blocks the proliferation and activation of pathogenic NK cells and specific T cell subsets induced by IL-2 and IL-15, without affecting the proliferation of regulatory T cells. FB102 inhibits IL-2/IL-15-induced activation of CD4+ and CD8+ T cells in in vitro disease models. FB102 is applicable to research related to celiac disease.
    FB102
  • HY-P990277
    Anti-Mouse CD31/PECAM-1 Antibody (390)
    Inhibitor
    Anti-Mouse CD31/PECAM-1 Antibody (390) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse CD31/PECAM-1. Anti-Mouse CD31/PECAM-1 Antibody (390) reacts with mouse CD31, also known as PECAM-1 (platelet endothelial cell adhesion molecule). Anti-Mouse CD31/PECAM-1 Antibody (390) inhibits angiogenesis. Anti-Mouse CD31/PECAM-1 Antibody (390) can be used for the research of cancer, such as A549 tumor.
    Anti-Mouse CD31/PECAM-1 Antibody (390)
  • HY-P99834
    Crefmirlimab
    Inhibitor
    Crefmirlimab (IAB22M2C; ImaginAb) is a humanized CD8-specific single-domain antibody. Conjugation of Crefmirlimab with radioisotopes (e.g., 89Zr) enables tumor immune infiltration assessment, autoimmune disease detection, and immunotherapy response monitoring. Crefmirlimab is applicable for cancer research.
    Crefmirlimab
  • HY-P991364
    Aldastotug
    Inhibitor 99.9%
    Aldastotug (PYX-106; BSI-060T) is a human monoclonal antibody (mAb) targeting Siglec-15/CD33L3. Aldastotug reverses Siglec-15-mediated immunosuppression and enhances T-cell proliferation. Aldastotug induces significantly increased levels of IFNγ and TNFα in T cells. Aldastotug can be used in cancer immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
    Aldastotug